epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Akeega

niraparib/ abiraterone acetate

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  TAB: 50 mg/500 mg, 100 mg/500 mg

Special Note

[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

BRCA-mutated prostate CA, metastatic

[castration-sensitive disease]
Dose: 200 mg/1000 mg PO qd; Info: use with prednisone 5 mg PO daily; also use with GnRH analog in patients without bilateral orchiectomy; give at least 1h before or 2h after meals; do not cut/crush/chew tab
[castration-resistant disease]
Dose: 200 mg/1000 mg PO qd; Info: use with prednisone 10 mg PO daily; also use with GnRH analog in patients without bilateral orchiectomy; give at least 1h before or 2h after meals; do not cut/crush/chew tab

renal dosing

[see below]
CrCl >30: no adjustment; CrCl <30: not defined, caution advised

hepatic dosing

[see below]
Child-Pugh Class B or C: avoid use

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@69b5be46
  • hypersensitivity to drug or ingredient
  • incomplete hematologic toxicity recovery after prior chemo use
  • HTN, uncontrolled
  • hypokalemia
  • hepatic impairment, Child-Pugh Class B-C
  • avoid: handling drug (pregnant or potentially pregnant individuals)
  • avoid: Ra-223 use during and for at least 5 days after D/C
  • caution: CrCl <30
  • caution: cardiovascular disease
  • caution: heart failure
  • caution: MI, recent
  • caution: ventricular arrhythmia
  • caution: adrenal insufficiency
  • caution: hypoglycemia risk

Drug Interactions .

Overview

abiraterone acetate

antiandrogen

Interaction Characteristics:
  • CYP3A4 substrate
  • CYP2C8 inhibitor, weak
  • CYP2D6 inhibitor, moderate
  • hypertensive effects
  • hypokalemia
  • rhabdomyolysis

niraparib

PARP inhibitor

Interaction Characteristics:
  • MATE1 inhibitor
  • MATE2-K inhibitor
  • hypertensive effects
  • myelosuppressive oncologic agent

Contraindicated

  • eliglustat
  • Akeega (niraparib/ abiraterone acetate)
    +
    eliglustat
    1 interaction

    Contraindicated

    abiraterone acetate + eliglustat

    CYP2D6 EM: contraindicated if Child-Pugh Class A or if also combined w/ moderate to strong CYP3A4 inhibitor; otherwise, monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 IM: contraindicated if also combined w/ moderate to strong CYP3A4 inhibitor; otherwise, monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 PM: contraindicated if also combined w/ strong CYP3A4 inhibitor; avoid combo if also combined w/ weak to moderate CYP3A4 inhibitor; otherwise, monitor ECG: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • thioridazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    thioridazine
    1 interaction

    Contraindicated

    abiraterone acetate + thioridazine

    contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

Avoid/Use Alternative

  • amphetamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    amphetamine
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + amphetamine

    consider alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration; decr. amphetamine start dose: combo may incr. amphetamine levels, risk of HTN, serotonin syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

    Monitor/Modify Tx

    niraparib + amphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • apalutamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    apalutamide
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + apalutamide

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • arsenic trioxide
  • Akeega (niraparib/ abiraterone acetate)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + arsenic trioxide

    use alternative or monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • butalbital
  • Akeega (niraparib/ abiraterone acetate)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + butalbital

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • carbamazepine
  • Akeega (niraparib/ abiraterone acetate)
    +
    carbamazepine
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + carbamazepine

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • chloramphenicol
  • Akeega (niraparib/ abiraterone acetate)
    +
    chloramphenicol
    1 interaction

    Avoid/Use Alternative

    niraparib + chloramphenicol

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cladribine oral
  • Akeega (niraparib/ abiraterone acetate)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    niraparib + cladribine oral

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • codeine
  • Akeega (niraparib/ abiraterone acetate)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + codeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. codeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite morphine levels, efficacy (hepatic metabolism inhibited, decr. conversion to morphine)

  • deferiprone
  • Akeega (niraparib/ abiraterone acetate)
    +
    deferiprone
    1 interaction

    Avoid/Use Alternative

    niraparib + deferiprone

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dexrazoxane
  • Akeega (niraparib/ abiraterone acetate)
    +
    dexrazoxane
    1 interaction

    Avoid/Use Alternative

    niraparib + dexrazoxane

    monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use; otherwise, avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

  • dextroamphetamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    dextroamphetamine
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + dextroamphetamine

    consider alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration; decr. dextroamphetamine start dose: combo may incr. dextroamphetamine levels, risk of HTN, serotonin syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

    Monitor/Modify Tx

    niraparib + dextroamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dihydrocodeine
  • Akeega (niraparib/ abiraterone acetate)
    +
    dihydrocodeine
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + dihydrocodeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metabolism inhibited, decr. conversion to dihydromorphine)

  • dofetilide
  • Akeega (niraparib/ abiraterone acetate)
    +
    dofetilide
    1 interaction

    Avoid/Use Alternative

    niraparib + dofetilide

    consider alternative or monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport possibly inhibited)

  • doxorubicin
  • Akeega (niraparib/ abiraterone acetate)
    +
    doxorubicin
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + doxorubicin

    avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

  • encorafenib
  • Akeega (niraparib/ abiraterone acetate)
    +
    encorafenib
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + encorafenib

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • enzalutamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    enzalutamide
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + enzalutamide

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • epinephrine inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    epinephrine inhaled
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fexinidazole
  • Akeega (niraparib/ abiraterone acetate)
    +
    fexinidazole
    2 interactions

    Avoid/Use Alternative

    niraparib + fexinidazole

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

    Monitor/Modify Tx

    abiraterone acetate + fexinidazole

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • fosphenytoin
  • Akeega (niraparib/ abiraterone acetate)
    +
    fosphenytoin
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + fosphenytoin

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • furosemide
  • Akeega (niraparib/ abiraterone acetate)
    +
    furosemide
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + furosemide

    use alternative or monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + furosemide

    use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ganciclovir
  • Akeega (niraparib/ abiraterone acetate)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    niraparib + ganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ivosidenib
  • Akeega (niraparib/ abiraterone acetate)
    +
    ivosidenib
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + ivosidenib

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • lisdexamfetamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    lisdexamfetamine
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + lisdexamfetamine

    use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, HTN, other adverse effects (hepatic metabolism inhibited, additive effects)

    Monitor/Modify Tx

    niraparib + lisdexamfetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lumacaftor/ivacaftor
  • Akeega (niraparib/ abiraterone acetate)
    +
    lumacaftor/ ivacaftor
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + lumacaftor/ ivacaftor

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid, monitor BP: combo may decr. abiraterone levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    Monitor/Modify Tx

    niraparib + lumacaftor/ ivacaftor

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methadone
  • Akeega (niraparib/ abiraterone acetate)
    +
    methadone
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + methadone

    use alternative or monitor respiratory rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • midodrine
  • Akeega (niraparib/ abiraterone acetate)
    +
    midodrine
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

  • mitotane
  • Akeega (niraparib/ abiraterone acetate)
    +
    mitotane
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + mitotane

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • oliceridine
  • Akeega (niraparib/ abiraterone acetate)
    +
    oliceridine
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + oliceridine

    use alternative or monitor respiratory rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • palifermin
  • Akeega (niraparib/ abiraterone acetate)
    +
    palifermin
    1 interaction

    Avoid/Use Alternative

    niraparib + palifermin

    avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

  • penicillamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    penicillamine
    1 interaction

    Avoid/Use Alternative

    niraparib + penicillamine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentobarbital
  • Akeega (niraparib/ abiraterone acetate)
    +
    pentobarbital
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + pentobarbital

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • phenobarbital
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + phenobarbital

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • phenytoin
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenytoin
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + phenytoin

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • pimozide
  • Akeega (niraparib/ abiraterone acetate)
    +
    pimozide
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + pimozide

    avoid combo: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • pirfenidone
  • Akeega (niraparib/ abiraterone acetate)
    +
    pirfenidone
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + pirfenidone

    avoid combo if also combined w/ mod-strong CYP1A2 inhibitor; otherwise, caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

  • primaquine
  • Akeega (niraparib/ abiraterone acetate)
    +
    primaquine
    1 interaction

    Avoid/Use Alternative

    niraparib + primaquine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • primidone
  • Akeega (niraparib/ abiraterone acetate)
    +
    primidone
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + primidone

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • propafenone
  • Akeega (niraparib/ abiraterone acetate)
    +
    propafenone
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + propafenone

    if also combined w/ CYP3A4 inhibitor, avoid use; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

  • radium Ra 223 dichloride
  • Akeega (niraparib/ abiraterone acetate)
    +
    radium Ra 223 dichloride
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + radium Ra 223 dichloride

    avoid combo: combo may incr. risk of fractures, death (mechanism unknown)

    niraparib + radium Ra 223 dichloride

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • red yeast rice
  • Akeega (niraparib/ abiraterone acetate)
    +
    red yeast rice
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + red yeast rice

    use alternative or monitor CK, myopathy sx: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects, red yeast rice contains varying amounts of lovastatin)

  • rifabutin
  • Akeega (niraparib/ abiraterone acetate)
    +
    rifabutin
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + rifabutin

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

    Monitor/Modify Tx

    niraparib + rifabutin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rifampin
  • Akeega (niraparib/ abiraterone acetate)
    +
    rifampin
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + rifampin

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • ropeginterferon alfa-2b
  • Akeega (niraparib/ abiraterone acetate)
    +
    ropeginterferon alfa-2b
    1 interaction

    Avoid/Use Alternative

    niraparib + ropeginterferon alfa-2b

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • spironolactone
  • Akeega (niraparib/ abiraterone acetate)
    +
    spironolactone
    2 interactions

    Avoid/Use Alternative

    abiraterone acetate + spironolactone

    avoid combo: combo may decr. efficacy of both drugs (antagonistic effects, spironolactone may have androgen agonist activity in androgen-depleted state)

    Monitor/Modify Tx

    niraparib + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • St. John's wort
  • Akeega (niraparib/ abiraterone acetate)
    +
    St. John's wort
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + St. John's wort

    if abiraterone coformulated w/ niraparib, avoid combo; otherwise, use alternative or incr. abiraterone dosing frequency to bid: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • tamsulosin
  • Akeega (niraparib/ abiraterone acetate)
    +
    tamsulosin
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + tamsulosin

    avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • tramadol
  • Akeega (niraparib/ abiraterone acetate)
    +
    tramadol
    1 interaction

    Avoid/Use Alternative

    abiraterone acetate + tramadol

    use alternative or monitor respiratory rate, ECG, withdrawal sx: combo may incr. tramadol levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • valganciclovir
  • Akeega (niraparib/ abiraterone acetate)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    niraparib + valganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

Monitor/Modify Tx

  • abiraterone acetate
  • Akeega (niraparib/ abiraterone acetate)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    niraparib + abiraterone acetate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • acebutolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    acebutolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + acebutolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + acebutolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • acetazolamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    acetazolamide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + acetazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • albendazole
  • Akeega (niraparib/ abiraterone acetate)
    +
    albendazole
    1 interaction

    Monitor/Modify Tx

    niraparib + albendazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • albuterol
  • Akeega (niraparib/ abiraterone acetate)
    +
    albuterol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + albuterol

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + albuterol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • albuterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    albuterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + albuterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + albuterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • alemtuzumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    alemtuzumab
    1 interaction

    Monitor/Modify Tx

    niraparib + alemtuzumab

    monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

  • aliskiren
  • Akeega (niraparib/ abiraterone acetate)
    +
    aliskiren
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • allopurinol
  • Akeega (niraparib/ abiraterone acetate)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    niraparib + allopurinol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • almotriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    almotriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aloe
  • Akeega (niraparib/ abiraterone acetate)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + aloe

    monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

  • amiloride
  • Akeega (niraparib/ abiraterone acetate)
    +
    amiloride
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amiodarone
  • Akeega (niraparib/ abiraterone acetate)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + amiodarone

    monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • amlodipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    amlodipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amphotericin
  • Akeega (niraparib/ abiraterone acetate)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + amphotericin

    monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

  • angiotensin II
  • Akeega (niraparib/ abiraterone acetate)
    +
    angiotensin II
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

  • anti-thymocyte globulin
  • Akeega (niraparib/ abiraterone acetate)
    +
    anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    niraparib + anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • aprocitentan
  • Akeega (niraparib/ abiraterone acetate)
    +
    aprocitentan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • arformoterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    arformoterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + arformoterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + arformoterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aripiprazole oral
  • Akeega (niraparib/ abiraterone acetate)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + aripiprazole oral

    consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • armodafinil
  • Akeega (niraparib/ abiraterone acetate)
    +
    armodafinil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + armodafinil

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + armodafinil

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asciminib
  • Akeega (niraparib/ abiraterone acetate)
    +
    asciminib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asparaginase
  • Akeega (niraparib/ abiraterone acetate)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + asparaginase

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • atenolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    atenolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + atenolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + atenolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • atidarsagene autotemcel
  • Akeega (niraparib/ abiraterone acetate)
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    niraparib + atidarsagene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • atogepant
  • Akeega (niraparib/ abiraterone acetate)
    +
    atogepant
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atomoxetine
  • Akeega (niraparib/ abiraterone acetate)
    +
    atomoxetine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + atomoxetine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + atomoxetine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atorvastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + atorvastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • atropine ophthalmic
  • Akeega (niraparib/ abiraterone acetate)
    +
    atropine ophthalmic
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • auranofin
  • Akeega (niraparib/ abiraterone acetate)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    niraparib + auranofin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • axitinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    axitinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • azathioprine
  • Akeega (niraparib/ abiraterone acetate)
    +
    azathioprine
    1 interaction

    Monitor/Modify Tx

    niraparib + azathioprine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • azilsartan medoxomil
  • Akeega (niraparib/ abiraterone acetate)
    +
    azilsartan medoxomil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • balsalazide
  • Akeega (niraparib/ abiraterone acetate)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    niraparib + balsalazide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • baricitinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    niraparib + baricitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • benazepril
  • Akeega (niraparib/ abiraterone acetate)
    +
    benazepril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benznidazole
  • Akeega (niraparib/ abiraterone acetate)
    +
    benznidazole
    1 interaction

    Monitor/Modify Tx

    niraparib + benznidazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • benzphetamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    benzphetamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + benzphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + benzphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • betamethasone
  • Akeega (niraparib/ abiraterone acetate)
    +
    betamethasone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + betamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + betamethasone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • betaxolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    betaxolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + betaxolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + betaxolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • betibeglogene autotemcel
  • Akeega (niraparib/ abiraterone acetate)
    +
    betibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    niraparib + betibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • bevacizumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    bevacizumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bismuth subsalicylate
  • Akeega (niraparib/ abiraterone acetate)
    +
    bismuth subsalicylate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

    niraparib + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • bisoprolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    bisoprolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + bisoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + bisoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bosentan
  • Akeega (niraparib/ abiraterone acetate)
    +
    bosentan
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + bosentan

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • brexpiprazole
  • Akeega (niraparib/ abiraterone acetate)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + brexpiprazole

    if also combined w/ moderate or strong CYP3A4 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • brigatinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    brigatinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + brigatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + brigatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • budesonide
  • Akeega (niraparib/ abiraterone acetate)
    +
    budesonide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + budesonide

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + budesonide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bumetanide
  • Akeega (niraparib/ abiraterone acetate)
    +
    bumetanide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + bumetanide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + bumetanide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • bupropion
  • Akeega (niraparib/ abiraterone acetate)
    +
    bupropion
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + bupropion

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + bupropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cabozantinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    cabozantinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + cabozantinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + cabozantinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • caffeine
  • Akeega (niraparib/ abiraterone acetate)
    +
    caffeine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + caffeine

    monitor BP; avoid excessive caffeine intake: combo may incr. risk of HTN (additive effects)

    niraparib + caffeine

    monitor BP; avoid excessive caffeine intake: combo may incr. risk of HTN (additive effects)

  • caffeine citrate
  • Akeega (niraparib/ abiraterone acetate)
    +
    caffeine citrate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + caffeine citrate

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + caffeine citrate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • candesartan cilexetil
  • Akeega (niraparib/ abiraterone acetate)
    +
    candesartan cilexetil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cannabis
  • Akeega (niraparib/ abiraterone acetate)
    +
    cannabis
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + cannabis

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + cannabis

    monitor BP: combo may incr. risk of HTN (additive effects)

  • captopril
  • Akeega (niraparib/ abiraterone acetate)
    +
    captopril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carfilzomib
  • Akeega (niraparib/ abiraterone acetate)
    +
    carfilzomib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + carfilzomib

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + carfilzomib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • carvedilol
  • Akeega (niraparib/ abiraterone acetate)
    +
    carvedilol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + carvedilol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + carvedilol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • celecoxib
  • Akeega (niraparib/ abiraterone acetate)
    +
    celecoxib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cenobamate
  • Akeega (niraparib/ abiraterone acetate)
    +
    cenobamate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + cenobamate

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • cetuximab
  • Akeega (niraparib/ abiraterone acetate)
    +
    cetuximab
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + cetuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chlorothiazide
  • Akeega (niraparib/ abiraterone acetate)
    +
    chlorothiazide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + chlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + chlorothiazide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • chlorthalidone
  • Akeega (niraparib/ abiraterone acetate)
    +
    chlorthalidone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + chlorthalidone

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + chlorthalidone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cidofovir
  • Akeega (niraparib/ abiraterone acetate)
    +
    cidofovir
    1 interaction

    Monitor/Modify Tx

    niraparib + cidofovir

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cisplatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + cisplatin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • clevidipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    clevidipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clonidine
  • Akeega (niraparib/ abiraterone acetate)
    +
    clonidine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clozapine
  • Akeega (niraparib/ abiraterone acetate)
    +
    clozapine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + clozapine

    monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

    niraparib + clozapine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cocaine
  • Akeega (niraparib/ abiraterone acetate)
    +
    cocaine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + cocaine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + cocaine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • colchicine
  • Akeega (niraparib/ abiraterone acetate)
    +
    colchicine
    1 interaction

    Monitor/Modify Tx

    niraparib + colchicine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • copanlisib
  • Akeega (niraparib/ abiraterone acetate)
    +
    copanlisib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects; copanlisib may cause infusion-related HTN)

    niraparib + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects; copanlisib may cause infusion-related HTN)

  • copper histidinate
  • Akeega (niraparib/ abiraterone acetate)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    niraparib + copper histidinate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • corticotropin
  • Akeega (niraparib/ abiraterone acetate)
    +
    corticotropin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + corticotropin

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + corticotropin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • cortisone
  • Akeega (niraparib/ abiraterone acetate)
    +
    cortisone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + cortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + cortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • crizotinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    crizotinib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + crizotinib

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • cyclophosphamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    niraparib + cyclophosphamide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cyclosporine
  • Akeega (niraparib/ abiraterone acetate)
    +
    cyclosporine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + cyclosporine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + cyclosporine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dabrafenib
  • Akeega (niraparib/ abiraterone acetate)
    +
    dabrafenib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + dabrafenib

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • danazol
  • Akeega (niraparib/ abiraterone acetate)
    +
    danazol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dapsone
  • Akeega (niraparib/ abiraterone acetate)
    +
    dapsone
    1 interaction

    Monitor/Modify Tx

    niraparib + dapsone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • darbepoetin alfa
  • Akeega (niraparib/ abiraterone acetate)
    +
    darbepoetin alfa
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • decitabine
  • Akeega (niraparib/ abiraterone acetate)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

  • deferasirox
  • Akeega (niraparib/ abiraterone acetate)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    niraparib + deferasirox

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • deflazacort
  • Akeega (niraparib/ abiraterone acetate)
    +
    deflazacort
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + deflazacort

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + deflazacort

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desipramine
  • Akeega (niraparib/ abiraterone acetate)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + desipramine

    monitor ECG; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • desmopressin
  • Akeega (niraparib/ abiraterone acetate)
    +
    desmopressin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desvenlafaxine
  • Akeega (niraparib/ abiraterone acetate)
    +
    desvenlafaxine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + desvenlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + desvenlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • deuruxolitinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    niraparib + deuruxolitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • deutetrabenazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    deutetrabenazine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + deutetrabenazine

    monitor ECG: combo may incr. deutetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dexamethasone
  • Akeega (niraparib/ abiraterone acetate)
    +
    dexamethasone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + dexamethasone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + dexamethasone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dexmethylphenidate
  • Akeega (niraparib/ abiraterone acetate)
    +
    dexmethylphenidate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + dexmethylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + dexmethylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dichlorphenamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    dichlorphenamide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + dichlorphenamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • diclofenac
  • Akeega (niraparib/ abiraterone acetate)
    +
    diclofenac
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac topical
  • Akeega (niraparib/ abiraterone acetate)
    +
    diclofenac topical
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diethylpropion
  • Akeega (niraparib/ abiraterone acetate)
    +
    diethylpropion
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + diethylpropion

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + diethylpropion

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diflunisal
  • Akeega (niraparib/ abiraterone acetate)
    +
    diflunisal
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • digoxin
  • Akeega (niraparib/ abiraterone acetate)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + digoxin

    monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

  • dihydroergotamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    dihydroergotamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + dihydroergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

    niraparib + dihydroergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • diltiazem
  • Akeega (niraparib/ abiraterone acetate)
    +
    diltiazem
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dinutuximab
  • Akeega (niraparib/ abiraterone acetate)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + dinutuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • dobutamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    dobutamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + dobutamine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + dobutamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dopamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    dopamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + dopamine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + dopamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxapram
  • Akeega (niraparib/ abiraterone acetate)
    +
    doxapram
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + doxapram

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + doxapram

    monitor BP: combo may incr. risk of HTN (additive effects)

  • doxazosin
  • Akeega (niraparib/ abiraterone acetate)
    +
    doxazosin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dronabinol
  • Akeega (niraparib/ abiraterone acetate)
    +
    dronabinol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + dronabinol

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + dronabinol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • droxidopa
  • Akeega (niraparib/ abiraterone acetate)
    +
    droxidopa
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

    niraparib + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

  • efavirenz
  • Akeega (niraparib/ abiraterone acetate)
    +
    efavirenz
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + efavirenz

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • efbemalenograstim alfa
  • Akeega (niraparib/ abiraterone acetate)
    +
    efbemalenograstim alfa
    1 interaction

    Monitor/Modify Tx

    niraparib + efbemalenograstim alfa

    admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

  • eflapegrastim (G-CSF)
  • Akeega (niraparib/ abiraterone acetate)
    +
    eflapegrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    niraparib + eflapegrastim (G-CSF)

    admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

  • eletriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    eletriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • elivaldogene autotemcel
  • Akeega (niraparib/ abiraterone acetate)
    +
    elivaldogene autotemcel
    1 interaction

    Monitor/Modify Tx

    niraparib + elivaldogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • emapalumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    emapalumab
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + emapalumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • enalapril
  • Akeega (niraparib/ abiraterone acetate)
    +
    enalapril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Akeega (niraparib/ abiraterone acetate)
    +
    enalaprilat
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ephedra
  • Akeega (niraparib/ abiraterone acetate)
    +
    ephedra
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ephedra

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ephedra

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine injection
  • Akeega (niraparib/ abiraterone acetate)
    +
    ephedrine injection
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ephedrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ephedrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ephedrine oral
  • Akeega (niraparib/ abiraterone acetate)
    +
    ephedrine oral
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ephedrine oral

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ephedrine oral

    monitor BP: combo may incr. risk of HTN (additive effects)

  • epinephrine
  • Akeega (niraparib/ abiraterone acetate)
    +
    epinephrine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + epinephrine

    monitor BP, potassium, ECG: combo may incr. risk of HTN, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

    niraparib + epinephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eplerenone
  • Akeega (niraparib/ abiraterone acetate)
    +
    eplerenone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + eplerenone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + eplerenone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epoetin alfa
  • Akeega (niraparib/ abiraterone acetate)
    +
    epoetin alfa
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eptinezumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    eptinezumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • erenumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    erenumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ergotamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    ergotamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

    niraparib + ergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • esketamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    esketamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + esketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + esketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • esmolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    esmolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + esmolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + esmolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • estetrol (contraceptive)
  • Akeega (niraparib/ abiraterone acetate)
    +
    estetrol (contraceptive)
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • estradiol (contraceptive)
  • Akeega (niraparib/ abiraterone acetate)
    +
    estradiol (contraceptive)
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ethacrynic acid
  • Akeega (niraparib/ abiraterone acetate)
    +
    ethacrynic acid
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ethacrynic acid

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + ethacrynic acid

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ethanol (alcoholic beverage)
  • Akeega (niraparib/ abiraterone acetate)
    +
    ethanol (alcoholic beverage)
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

    niraparib + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • ethinyl estradiol (contraceptive)
  • Akeega (niraparib/ abiraterone acetate)
    +
    ethinyl estradiol (contraceptive)
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etodolac
  • Akeega (niraparib/ abiraterone acetate)
    +
    etodolac
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etrasimod
  • Akeega (niraparib/ abiraterone acetate)
    +
    etrasimod
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etravirine
  • Akeega (niraparib/ abiraterone acetate)
    +
    etravirine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + etravirine

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • etuvetidigene autotemcel
  • Akeega (niraparib/ abiraterone acetate)
    +
    etuvetidigene autotemcel
    1 interaction

    Monitor/Modify Tx

    niraparib + etuvetidigene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • everolimus
  • Akeega (niraparib/ abiraterone acetate)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    niraparib + everolimus

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • exagamglogene autotemcel
  • Akeega (niraparib/ abiraterone acetate)
    +
    exagamglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    niraparib + exagamglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • felodipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    felodipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + felodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + felodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenfluramine
  • Akeega (niraparib/ abiraterone acetate)
    +
    fenfluramine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenoldopam
  • Akeega (niraparib/ abiraterone acetate)
    +
    fenoldopam
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Akeega (niraparib/ abiraterone acetate)
    +
    fenoprofen
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • filgrastim (G-CSF)
  • Akeega (niraparib/ abiraterone acetate)
    +
    filgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    niraparib + filgrastim (G-CSF)

    admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

  • fingolimod
  • Akeega (niraparib/ abiraterone acetate)
    +
    fingolimod
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • flecainide
  • Akeega (niraparib/ abiraterone acetate)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + flecainide

    monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • flucytosine
  • Akeega (niraparib/ abiraterone acetate)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    niraparib + flucytosine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fludrocortisone
  • Akeega (niraparib/ abiraterone acetate)
    +
    fludrocortisone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fludrocortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + fludrocortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fluphenazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    niraparib + fluphenazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • flurbiprofen
  • Akeega (niraparib/ abiraterone acetate)
    +
    flurbiprofen
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fluvastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    fluvastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + fluvastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • formoterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    formoterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + formoterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + formoterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • foscarnet
  • Akeega (niraparib/ abiraterone acetate)
    +
    foscarnet
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + foscarnet

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

    niraparib + foscarnet

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fosfomycin injection
  • Akeega (niraparib/ abiraterone acetate)
    +
    fosfomycin injection
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fosfomycin injection

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    niraparib + fosfomycin injection

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fosinopril
  • Akeega (niraparib/ abiraterone acetate)
    +
    fosinopril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fostamatinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    fostamatinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + fostamatinib

    monitor CBC, BP: combo may incr. risk of myelosuppression, HTN (additive effects)

  • fremanezumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    fremanezumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • frovatriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    frovatriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    fruquintinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • galcanezumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    galcanezumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • givinostat
  • Akeega (niraparib/ abiraterone acetate)
    +
    givinostat
    1 interaction

    Monitor/Modify Tx

    niraparib + givinostat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • guanfacine
  • Akeega (niraparib/ abiraterone acetate)
    +
    guanfacine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hoodia
  • Akeega (niraparib/ abiraterone acetate)
    +
    hoodia
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + hoodia

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + hoodia

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydralazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    hydralazine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Akeega (niraparib/ abiraterone acetate)
    +
    hydrochlorothiazide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + hydrochlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + hydrochlorothiazide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrocortisone
  • Akeega (niraparib/ abiraterone acetate)
    +
    hydrocortisone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + hydrocortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + hydrocortisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydroxocobalamin IV
  • Akeega (niraparib/ abiraterone acetate)
    +
    hydroxocobalamin IV
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydroxychloroquine
  • Akeega (niraparib/ abiraterone acetate)
    +
    hydroxychloroquine
    1 interaction

    Monitor/Modify Tx

    niraparib + hydroxychloroquine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • hydroxyurea
  • Akeega (niraparib/ abiraterone acetate)
    +
    hydroxyurea
    1 interaction

    Monitor/Modify Tx

    niraparib + hydroxyurea

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ibrutinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    ibrutinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ibrutinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ibrutinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibuprofen
  • Akeega (niraparib/ abiraterone acetate)
    +
    ibuprofen
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • iloperidone
  • Akeega (niraparib/ abiraterone acetate)
    +
    iloperidone
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + iloperidone

    monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • imipramine
  • Akeega (niraparib/ abiraterone acetate)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + imipramine

    monitor imipramine levels: combo may incr. imipramine levels, risk of adverse effects (hepatic metabolism inhibited)

  • indapamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    indapamide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + indapamide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + indapamide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • indomethacin
  • Akeega (niraparib/ abiraterone acetate)
    +
    indomethacin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • insulin
  • Akeega (niraparib/ abiraterone acetate)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + insulin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • interferon beta 1a
  • Akeega (niraparib/ abiraterone acetate)
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    niraparib + interferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon beta 1b
  • Akeega (niraparib/ abiraterone acetate)
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    niraparib + interferon beta 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon gamma 1b
  • Akeega (niraparib/ abiraterone acetate)
    +
    interferon gamma 1b
    1 interaction

    Monitor/Modify Tx

    niraparib + interferon gamma 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • irbesartan
  • Akeega (niraparib/ abiraterone acetate)
    +
    irbesartan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • isoproterenol
  • Akeega (niraparib/ abiraterone acetate)
    +
    isoproterenol
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + isoproterenol

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • isradipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    isradipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ketamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    ketamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ketamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketoprofen
  • Akeega (niraparib/ abiraterone acetate)
    +
    ketoprofen
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketorolac
  • Akeega (niraparib/ abiraterone acetate)
    +
    ketorolac
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • labetalol
  • Akeega (niraparib/ abiraterone acetate)
    +
    labetalol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + labetalol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + labetalol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lanreotide
  • Akeega (niraparib/ abiraterone acetate)
    +
    lanreotide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leflunomide
  • Akeega (niraparib/ abiraterone acetate)
    +
    leflunomide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + leflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + leflunomide

    monitor CBC, BP: combo may incr. risk of myelosuppression, HTN (additive effects)

  • lenalidomide
  • Akeega (niraparib/ abiraterone acetate)
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + lenalidomide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • lenvatinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    lenvatinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • levalbuterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    levalbuterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + levalbuterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + levalbuterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • levomilnacipran
  • Akeega (niraparib/ abiraterone acetate)
    +
    levomilnacipran
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + levomilnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + levomilnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • licorice
  • Akeega (niraparib/ abiraterone acetate)
    +
    licorice
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + licorice

    monitor BP, potassium w/ large amounts of licorice: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + licorice

    monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects)

  • linezolid
  • Akeega (niraparib/ abiraterone acetate)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    niraparib + linezolid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lisinopril
  • Akeega (niraparib/ abiraterone acetate)
    +
    lisinopril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lonafarnib
  • Akeega (niraparib/ abiraterone acetate)
    +
    lonafarnib
    1 interaction

    Monitor/Modify Tx

    niraparib + lonafarnib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lopinavir/ritonavir
  • Akeega (niraparib/ abiraterone acetate)
    +
    lopinavir/ ritonavir
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + lopinavir/ ritonavir

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • lorlatinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    lorlatinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + lorlatinib

    monitor BP; if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    niraparib + lorlatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • losartan
  • Akeega (niraparib/ abiraterone acetate)
    +
    losartan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lovastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    lovastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + lovastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • lovotibeglogene autotemcel
  • Akeega (niraparib/ abiraterone acetate)
    +
    lovotibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    niraparib + lovotibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • luspatercept
  • Akeega (niraparib/ abiraterone acetate)
    +
    luspatercept
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Akeega (niraparib/ abiraterone acetate)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    niraparib + lymphocyte immune globulin, anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • magnesium citrate
  • Akeega (niraparib/ abiraterone acetate)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + magnesium citrate

    monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium salicylate
  • Akeega (niraparib/ abiraterone acetate)
    +
    magnesium salicylate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

    niraparib + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • mannitol
  • Akeega (niraparib/ abiraterone acetate)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + mannitol

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • mavacamten
  • Akeega (niraparib/ abiraterone acetate)
    +
    mavacamten
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + mavacamten

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • meclofenamate
  • Akeega (niraparib/ abiraterone acetate)
    +
    meclofenamate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mefenamic acid
  • Akeega (niraparib/ abiraterone acetate)
    +
    mefenamic acid
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

  • meloxicam
  • Akeega (niraparib/ abiraterone acetate)
    +
    meloxicam
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mercaptopurine
  • Akeega (niraparib/ abiraterone acetate)
    +
    mercaptopurine
    1 interaction

    Monitor/Modify Tx

    niraparib + mercaptopurine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    niraparib + mesalamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine rectal
  • Akeega (niraparib/ abiraterone acetate)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    niraparib + mesalamine rectal

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • metformin
  • Akeega (niraparib/ abiraterone acetate)
    +
    metformin
    1 interaction

    Monitor/Modify Tx

    niraparib + metformin

    monitor metabolic acidosis s/sx: combo may incr. metformin levels, risk of lactic acidosis, other adverse effects (renal transport possibly inhibited)

  • methamphetamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    methamphetamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + methamphetamine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methazolamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    methazolamide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + methazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • methotrexate
  • Akeega (niraparib/ abiraterone acetate)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    niraparib + methotrexate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Akeega (niraparib/ abiraterone acetate)
    +
    methoxy polyethylene glycol-epoetin beta
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methyldopa
  • Akeega (niraparib/ abiraterone acetate)
    +
    methyldopa
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Akeega (niraparib/ abiraterone acetate)
    +
    methylergonovine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methylergonovine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

    niraparib + methylergonovine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • methylphenidate
  • Akeega (niraparib/ abiraterone acetate)
    +
    methylphenidate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + methylphenidate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methylprednisolone
  • Akeega (niraparib/ abiraterone acetate)
    +
    methylprednisolone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methylprednisolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + methylprednisolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methyltestosterone
  • Akeega (niraparib/ abiraterone acetate)
    +
    methyltestosterone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metoclopramide
  • Akeega (niraparib/ abiraterone acetate)
    +
    metoclopramide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metolazone
  • Akeega (niraparib/ abiraterone acetate)
    +
    metolazone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + metolazone

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + metolazone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • metoprolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    metoprolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + metoprolol

    monitor BP, HR: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

    niraparib + metoprolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mifepristone
  • Akeega (niraparib/ abiraterone acetate)
    +
    mifepristone
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + mifepristone

    monitor potassium if daily mifepristone use: combo may incr. risk of hypokalemia (additive effects)

  • milnacipran
  • Akeega (niraparib/ abiraterone acetate)
    +
    milnacipran
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + milnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + milnacipran

    monitor BP: combo may incr. risk of HTN (additive effects)

  • milsaperidone
  • Akeega (niraparib/ abiraterone acetate)
    +
    milsaperidone
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + milsaperidone

    monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • minoxidil
  • Akeega (niraparib/ abiraterone acetate)
    +
    minoxidil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Akeega (niraparib/ abiraterone acetate)
    +
    mirabegron
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mitapivat
  • Akeega (niraparib/ abiraterone acetate)
    +
    mitapivat
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + mitapivat

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • modafinil
  • Akeega (niraparib/ abiraterone acetate)
    +
    modafinil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + modafinil

    monitor BP; if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    niraparib + modafinil

    monitor BP: combo may incr. risk of HTN (additive effects)

  • moexipril
  • Akeega (niraparib/ abiraterone acetate)
    +
    moexipril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • motixafortide
  • Akeega (niraparib/ abiraterone acetate)
    +
    motixafortide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + motixafortide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • mycophenolate mofetil
  • Akeega (niraparib/ abiraterone acetate)
    +
    mycophenolate mofetil
    1 interaction

    Monitor/Modify Tx

    niraparib + mycophenolate mofetil

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mycophenolic acid
  • Akeega (niraparib/ abiraterone acetate)
    +
    mycophenolic acid
    1 interaction

    Monitor/Modify Tx

    niraparib + mycophenolic acid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • nabumetone
  • Akeega (niraparib/ abiraterone acetate)
    +
    nabumetone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nadolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    nadolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nadolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + nadolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nafcillin
  • Akeega (niraparib/ abiraterone acetate)
    +
    nafcillin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + nafcillin

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • naproxen
  • Akeega (niraparib/ abiraterone acetate)
    +
    naproxen
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naratriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    naratriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naxitamab
  • Akeega (niraparib/ abiraterone acetate)
    +
    naxitamab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nebivolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    nebivolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nebivolol

    monitor BP, HR: combo may incr. nebivolol levels, risk of hypotension, bradycardia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

    niraparib + nebivolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • necitumumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + necitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • nicardipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    nicardipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nifedipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    nifedipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nifedipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + nifedipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nilotinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + nilotinib

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • nimodipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    nimodipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nimodipine

    monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

    niraparib + nimodipine

    monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

  • niraparib
  • Akeega (niraparib/ abiraterone acetate)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Akeega (niraparib/ abiraterone acetate)
    +
    nisoldipine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + nisoldipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + nisoldipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • norepinephrine
  • Akeega (niraparib/ abiraterone acetate)
    +
    norepinephrine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + norepinephrine

    monitor BP: combo may incr. risk of severe HTN (additive effects)

    niraparib + norepinephrine

    monitor BP: combo may incr. risk of severe HTN (additive effects)

  • nortriptyline
  • Akeega (niraparib/ abiraterone acetate)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + nortriptyline

    monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

  • obinutuzumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    obinutuzumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • olmesartan medoxomil
  • Akeega (niraparib/ abiraterone acetate)
    +
    olmesartan medoxomil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • olodaterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    olodaterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + olodaterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + olodaterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • olsalazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    niraparib + olsalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • osilodrostat
  • Akeega (niraparib/ abiraterone acetate)
    +
    osilodrostat
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + osilodrostat

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + osilodrostat

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxaprozin
  • Akeega (niraparib/ abiraterone acetate)
    +
    oxaprozin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxymetazoline nasal
  • Akeega (niraparib/ abiraterone acetate)
    +
    oxymetazoline nasal
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + oxymetazoline nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + oxymetazoline nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxytocin
  • Akeega (niraparib/ abiraterone acetate)
    +
    oxytocin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

    niraparib + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Akeega (niraparib/ abiraterone acetate)
    +
    ozanimod
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ozanimod

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + ozanimod

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • paclitaxel
  • Akeega (niraparib/ abiraterone acetate)
    +
    paclitaxel
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + paclitaxel

    monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • pacritinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + pacritinib

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • pamidronate
  • Akeega (niraparib/ abiraterone acetate)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + pamidronate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • panitumumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    panitumumab
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + panitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pazopanib
  • Akeega (niraparib/ abiraterone acetate)
    +
    pazopanib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pegfilgrastim (G-CSF)
  • Akeega (niraparib/ abiraterone acetate)
    +
    pegfilgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    niraparib + pegfilgrastim (G-CSF)

    admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

  • peginterferon alfa 2a
  • Akeega (niraparib/ abiraterone acetate)
    +
    peginterferon alfa 2a
    1 interaction

    Monitor/Modify Tx

    niraparib + peginterferon alfa 2a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • peginterferon beta 1a
  • Akeega (niraparib/ abiraterone acetate)
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    niraparib + peginterferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentamidine
  • Akeega (niraparib/ abiraterone acetate)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    niraparib + pentamidine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • perindopril
  • Akeega (niraparib/ abiraterone acetate)
    +
    perindopril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • perphenazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    perphenazine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + perphenazine

    consider decr. perphenazine dose: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

  • pexidartinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    pexidartinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + pexidartinib

    monitor BP; if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy; may incr. risk of HTN (hepatic metabolism induced; additive effects)

    niraparib + pexidartinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phendimetrazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    phendimetrazine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phendimetrazine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + phendimetrazine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenoxybenzamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenoxybenzamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Akeega (niraparib/ abiraterone acetate)
    +
    phentermine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phentermine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + phentermine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phentolamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    phentolamine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenylephrine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phenylephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + phenylephrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine injection
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenylephrine injection
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phenylephrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + phenylephrine injection

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine nasal
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenylephrine nasal
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phenylephrine nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + phenylephrine nasal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phenylephrine ophthalmic
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenylephrine ophthalmic
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phenylephrine ophthalmic

    monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN (additive effects)

    niraparib + phenylephrine ophthalmic

    monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN (additive effects)

  • phenylephrine rectal
  • Akeega (niraparib/ abiraterone acetate)
    +
    phenylephrine rectal
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + phenylephrine rectal

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + phenylephrine rectal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pindolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    pindolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + pindolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + pindolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pioglitazone
  • Akeega (niraparib/ abiraterone acetate)
    +
    pioglitazone
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + pioglitazone

    monitor glucose: combo may incr. pioglitazone levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • piroxicam
  • Akeega (niraparib/ abiraterone acetate)
    +
    piroxicam
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pitavastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    pitavastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + pitavastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • pitolisant
  • Akeega (niraparib/ abiraterone acetate)
    +
    pitolisant
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + pitolisant

    monitor ECG: combo may incr. pitolisant levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • polyethylene glycol
  • Akeega (niraparib/ abiraterone acetate)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + polyethylene glycol

    monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • polyethylene glycol/electrolytes
  • Akeega (niraparib/ abiraterone acetate)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + polyethylene glycol/ electrolytes

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • ponatinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    ponatinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ponesimod
  • Akeega (niraparib/ abiraterone acetate)
    +
    ponesimod
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • posaconazole
  • Akeega (niraparib/ abiraterone acetate)
    +
    posaconazole
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + posaconazole

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pralsetinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    pralsetinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + pralsetinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + pralsetinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pravastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    pravastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + pravastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • prazosin
  • Akeega (niraparib/ abiraterone acetate)
    +
    prazosin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Akeega (niraparib/ abiraterone acetate)
    +
    prednisolone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + prednisolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + prednisolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • prednisone
  • Akeega (niraparib/ abiraterone acetate)
    +
    prednisone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + prednisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + prednisone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • procainamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    procainamide
    1 interaction

    Monitor/Modify Tx

    niraparib + procainamide

    monitor procainamide levels, ECG: combo may incr. procainamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal transport possibly inhibited)

  • proguanil
  • Akeega (niraparib/ abiraterone acetate)
    +
    proguanil
    1 interaction

    Monitor/Modify Tx

    niraparib + proguanil

    monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

  • propranolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    propranolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + propranolol

    monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)

    niraparib + propranolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pseudoephedrine
  • Akeega (niraparib/ abiraterone acetate)
    +
    pseudoephedrine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + pseudoephedrine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + pseudoephedrine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pyrimethamine
  • Akeega (niraparib/ abiraterone acetate)
    +
    pyrimethamine
    1 interaction

    Monitor/Modify Tx

    niraparib + pyrimethamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • quetiapine
  • Akeega (niraparib/ abiraterone acetate)
    +
    quetiapine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

    niraparib + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

  • quinapril
  • Akeega (niraparib/ abiraterone acetate)
    +
    quinapril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramipril
  • Akeega (niraparib/ abiraterone acetate)
    +
    ramipril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    ramucirumab
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • regorafenib
  • Akeega (niraparib/ abiraterone acetate)
    +
    regorafenib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • repaglinide
  • Akeega (niraparib/ abiraterone acetate)
    +
    repaglinide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + repaglinide

    monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • repotrectinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    repotrectinib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + repotrectinib

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • ribavirin
  • Akeega (niraparib/ abiraterone acetate)
    +
    ribavirin
    1 interaction

    Monitor/Modify Tx

    niraparib + ribavirin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rifapentine
  • Akeega (niraparib/ abiraterone acetate)
    +
    rifapentine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + rifapentine

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • rimegepant
  • Akeega (niraparib/ abiraterone acetate)
    +
    rimegepant
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ripretinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    ripretinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rituximab
  • Akeega (niraparib/ abiraterone acetate)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    niraparib + rituximab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rizatriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    rizatriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ropinirole
  • Akeega (niraparib/ abiraterone acetate)
    +
    ropinirole
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ropinirole

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ropinirole

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rosiglitazone
  • Akeega (niraparib/ abiraterone acetate)
    +
    rosiglitazone
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + rosiglitazone

    monitor glucose: combo may incr. rosiglitazone levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • rosuvastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    rosuvastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + rosuvastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • rotigotine transdermal
  • Akeega (niraparib/ abiraterone acetate)
    +
    rotigotine transdermal
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + rotigotine transdermal

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + rotigotine transdermal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ruxolitinib topical
  • Akeega (niraparib/ abiraterone acetate)
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    niraparib + ruxolitinib topical

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sacituzumab govitecan
  • Akeega (niraparib/ abiraterone acetate)
    +
    sacituzumab govitecan
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sacituzumab govitecan

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • salmeterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    salmeterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + salmeterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + salmeterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • salsalate
  • Akeega (niraparib/ abiraterone acetate)
    +
    salsalate
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + salsalate

    monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

    niraparib + salsalate

    monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

  • sargramostim (GM-CSF)
  • Akeega (niraparib/ abiraterone acetate)
    +
    sargramostim (GM-CSF)
    1 interaction

    Monitor/Modify Tx

    niraparib + sargramostim (GM-CSF)

    admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

  • sarilumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    sarilumab
    1 interaction

    Monitor/Modify Tx

    niraparib + sarilumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • satralizumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    satralizumab
    1 interaction

    Monitor/Modify Tx

    niraparib + satralizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • selinexor
  • Akeega (niraparib/ abiraterone acetate)
    +
    selinexor
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + selinexor

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • selpercatinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    selpercatinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + selpercatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + selpercatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • simvastatin
  • Akeega (niraparib/ abiraterone acetate)
    +
    simvastatin
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + simvastatin

    consider monitoring CK: combo may incr. risk of myopathy, rhabdomyolysis (possible additive effects)

  • siponimod
  • Akeega (niraparib/ abiraterone acetate)
    +
    siponimod
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sirolimus
  • Akeega (niraparib/ abiraterone acetate)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    niraparib + sirolimus

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sirolimus albumin-bound
  • Akeega (niraparib/ abiraterone acetate)
    +
    sirolimus albumin-bound
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sirolimus albumin-bound

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium benzoate
  • Akeega (niraparib/ abiraterone acetate)
    +
    sodium benzoate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sodium benzoate

    monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylacetate
  • Akeega (niraparib/ abiraterone acetate)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sodium phenylacetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylbutyrate
  • Akeega (niraparib/ abiraterone acetate)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sodium phenylbutyrate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium polystyrene sulfonate
  • Akeega (niraparib/ abiraterone acetate)
    +
    sodium polystyrene sulfonate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sodium polystyrene sulfonate

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sodium thiosulfate
  • Akeega (niraparib/ abiraterone acetate)
    +
    sodium thiosulfate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sodium thiosulfate

    if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

  • solriamfetol
  • Akeega (niraparib/ abiraterone acetate)
    +
    solriamfetol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + solriamfetol

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + solriamfetol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sorafenib
  • Akeega (niraparib/ abiraterone acetate)
    +
    sorafenib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sotorasib
  • Akeega (niraparib/ abiraterone acetate)
    +
    sotorasib
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sotorasib

    if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

  • stiripentol
  • Akeega (niraparib/ abiraterone acetate)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    niraparib + stiripentol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • succimer
  • Akeega (niraparib/ abiraterone acetate)
    +
    succimer
    1 interaction

    Monitor/Modify Tx

    niraparib + succimer

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sulfasalazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    sulfasalazine
    1 interaction

    Monitor/Modify Tx

    niraparib + sulfasalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sulfate bowel prep
  • Akeega (niraparib/ abiraterone acetate)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + sulfate bowel prep

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sulindac
  • Akeega (niraparib/ abiraterone acetate)
    +
    sulindac
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sumatriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    sumatriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    sunitinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tacrolimus
  • Akeega (niraparib/ abiraterone acetate)
    +
    tacrolimus
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + tacrolimus

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + tacrolimus

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tafasitamab
  • Akeega (niraparib/ abiraterone acetate)
    +
    tafasitamab
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + tafasitamab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • tagraxofusp
  • Akeega (niraparib/ abiraterone acetate)
    +
    tagraxofusp
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • telmisartan
  • Akeega (niraparib/ abiraterone acetate)
    +
    telmisartan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • teplizumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    teplizumab
    1 interaction

    Monitor/Modify Tx

    niraparib + teplizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • terazosin
  • Akeega (niraparib/ abiraterone acetate)
    +
    terazosin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Akeega (niraparib/ abiraterone acetate)
    +
    terbutaline
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + terbutaline

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + terbutaline

    monitor BP: combo may incr. risk of HTN (additive effects)

  • teriflunomide
  • Akeega (niraparib/ abiraterone acetate)
    +
    teriflunomide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + teriflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + teriflunomide

    monitor CBC, BP: combo may incr. risk of myelosuppression, HTN (additive effects)

  • testosterone
  • Akeega (niraparib/ abiraterone acetate)
    +
    testosterone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tetrabenazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    tetrabenazine
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + tetrabenazine

    consider decr. tetrabenazine dose: combo may incr. tetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • thalidomide
  • Akeega (niraparib/ abiraterone acetate)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    niraparib + thalidomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • timolol
  • Akeega (niraparib/ abiraterone acetate)
    +
    timolol
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + timolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + timolol

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tivozanib
  • Akeega (niraparib/ abiraterone acetate)
    +
    tivozanib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • tocilizumab
  • Akeega (niraparib/ abiraterone acetate)
    +
    tocilizumab
    1 interaction

    Monitor/Modify Tx

    niraparib + tocilizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tofacitinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    niraparib + tofacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tolmetin
  • Akeega (niraparib/ abiraterone acetate)
    +
    tolmetin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • topiramate
  • Akeega (niraparib/ abiraterone acetate)
    +
    topiramate
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + topiramate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • torsemide
  • Akeega (niraparib/ abiraterone acetate)
    +
    torsemide
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + torsemide

    monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

    niraparib + torsemide

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • trametinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    trametinib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • trandolapril
  • Akeega (niraparib/ abiraterone acetate)
    +
    trandolapril
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triamcinolone
  • Akeega (niraparib/ abiraterone acetate)
    +
    triamcinolone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + triamcinolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    niraparib + triamcinolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • triamterene
  • Akeega (niraparib/ abiraterone acetate)
    +
    triamterene
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • trimethoprim
  • Akeega (niraparib/ abiraterone acetate)
    +
    trimethoprim
    1 interaction

    Monitor/Modify Tx

    niraparib + trimethoprim

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ubrogepant
  • Akeega (niraparib/ abiraterone acetate)
    +
    ubrogepant
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ubrogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ubrogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • upadacitinib
  • Akeega (niraparib/ abiraterone acetate)
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    niraparib + upadacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vadadustat
  • Akeega (niraparib/ abiraterone acetate)
    +
    vadadustat
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + vadadustat

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    niraparib + vadadustat

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • valproic acid
  • Akeega (niraparib/ abiraterone acetate)
    +
    valproic acid
    1 interaction

    Monitor/Modify Tx

    niraparib + valproic acid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • valsartan
  • Akeega (niraparib/ abiraterone acetate)
    +
    valsartan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vamorolone
  • Akeega (niraparib/ abiraterone acetate)
    +
    vamorolone
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + vamorolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + vamorolone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vancomycin
  • Akeega (niraparib/ abiraterone acetate)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    niraparib + vancomycin

    VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

  • vandetanib
  • Akeega (niraparib/ abiraterone acetate)
    +
    vandetanib
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + vandetanib

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + vandetanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vasopressin
  • Akeega (niraparib/ abiraterone acetate)
    +
    vasopressin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • venlafaxine
  • Akeega (niraparib/ abiraterone acetate)
    +
    venlafaxine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • verapamil
  • Akeega (niraparib/ abiraterone acetate)
    +
    verapamil
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + verapamil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

    niraparib + verapamil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vilanterol inhaled
  • Akeega (niraparib/ abiraterone acetate)
    +
    vilanterol inhaled
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + vilanterol inhaled

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    niraparib + vilanterol inhaled

    monitor BP: combo may incr. risk of HTN (additive effects)

  • viloxazine
  • Akeega (niraparib/ abiraterone acetate)
    +
    viloxazine
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + viloxazine

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + viloxazine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • voclosporin
  • Akeega (niraparib/ abiraterone acetate)
    +
    voclosporin
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • yohimbe
  • Akeega (niraparib/ abiraterone acetate)
    +
    yohimbe
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + yohimbe

    monitor BP, HR: combo may incr. yohimbe levels, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

    niraparib + yohimbe

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zavegepant
  • Akeega (niraparib/ abiraterone acetate)
    +
    zavegepant
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zidovudine
  • Akeega (niraparib/ abiraterone acetate)
    +
    zidovudine
    1 interaction

    Monitor/Modify Tx

    niraparib + zidovudine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ziv-aflibercept
  • Akeega (niraparib/ abiraterone acetate)
    +
    ziv-aflibercept
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zolmitriptan
  • Akeega (niraparib/ abiraterone acetate)
    +
    zolmitriptan
    2 interactions

    Monitor/Modify Tx

    abiraterone acetate + zolmitriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

    niraparib + zolmitriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zonisamide
  • Akeega (niraparib/ abiraterone acetate)
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    abiraterone acetate + zonisamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

  • lamivudine
  • Akeega (niraparib/ abiraterone acetate)
    +
    lamivudine
    1 interaction

    Caution Advised

    niraparib + lamivudine

    caution advised: combo may incr. lamivudine levels, risk of adverse effects (renal transport possibly inhibited)

  • memantine
  • Akeega (niraparib/ abiraterone acetate)
    +
    memantine
    1 interaction

    Caution Advised

    niraparib + memantine

    caution advised: combo may incr. memantine levels, risk of adverse effects (renal transport possibly inhibited)

  • pramipexole
  • Akeega (niraparib/ abiraterone acetate)
    +
    pramipexole
    1 interaction

    Caution Advised

    niraparib + pramipexole

    caution advised: combo may incr. pramipexole levels, risk of CNS depression, psychomotor impairment, other adverse effects (renal transport possibly inhibited)

  • tamoxifen
  • Akeega (niraparib/ abiraterone acetate)
    +
    tamoxifen
    1 interaction

    Caution Advised

    abiraterone acetate + tamoxifen

    caution advised: combo may decr. active tamoxifen metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • vortioxetine
  • Akeega (niraparib/ abiraterone acetate)
    +
    vortioxetine
    1 interaction

    Caution Advised

    abiraterone acetate + vortioxetine

    caution advised: combo may incr. vortioxetine levels, risk of adverse effects (hepatic metabolism inhibited)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@597ec41a
  • AML
  • myelodysplastic syndrome
  • anemia
  • thrombocytopenia
  • neutropenia
  • infection, serious
  • hemorrhage
  • fluid retention, severe
  • hypokalemia
  • QT prolongation
  • torsades de pointes
  • arrhythmia
  • stroke
  • pulmonary embolism
  • DVT
  • HTN
  • hypertensive crisis
  • cardiopulmonary arrest
  • cardiac failure
  • ischemic heart disease
  • hepatotoxicity
  • hepatitis, fulminant
  • hepatic failure, acute
  • acute kidney injury
  • adrenal insufficiency
  • fractures (in combo with radium Ra 223 dichloride)
  • mortality incr. (in combo with radium Ra 223 dichloride)
  • posterior reversible encephalopathy syndrome
  • rhabdomyolysis

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@53a08fa0
  • musculoskeletal pain
  • fatigue
  • constipation
  • HTN
  • nausea
  • edema
  • dyspnea
  • appetite decr.
  • vomiting
  • dizziness
  • infection
  • abdominal pain
  • hemorrhage
  • headache
  • cough
  • insomnia
  • weight loss
  • arrhythmia
  • hot flashes
  • diarrhea
  • cardiac failure
  • ischemic heart disease
  • fever
  • rash
  • stroke
  • pulmonary embolism
  • DVT
  • acute kidney injury
  • ALT or AST incr.
  • Hgb decr.
  • lymphocytes decr.
  • Plt decr.
  • alk phos incr.
  • neutrophils decr.
  • Cr incr.
  • potassium incr.
  • potassium decr.
  • bilirubin incr.

Safety/Monitoring .

Monitoring Parameters
CBC with diff at baseline, qwk x1mo, then q2wk x2mo, then qmo x9mo, then q2mo and as clinically indicated; BP, K at baseline, then at least qwk x2mo, then qmo; LFTs at baseline, then q2wk x3mo, then qmo; signs/symptoms of edema at least qwk x2mo, then qmo; adrenal function; glucose during and after tx if diabetes

Pregnancy/Lactation .

Pregnancy

Clinical Summary

while not indicated in female patients, pregnant individuals should avoid handling drug because of potential absorption through skin; risk of fetal harm based on animal data

Individuals of Reproductive Potential

avoid pregnancy by using effective contraception during tx and x4mo after D/C in male patients

Lactation

Clinical Summary

N/A; drug unlikely to be used while breastfeeding based on indication

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@64b41fa1

Metabolism: for niraparib: hydrolysis primarily, glucuronidation; CYP450: none; UGT: substrate (enzymes not defined); for abiraterone acetate: liver; CYP450: 3A4 substrate

Excretion: for niraparib: urine 47.5% (11% unchanged), feces 38.8% (19% unchanged); Half-life: 36h; for abiraterone acetate: feces 88% (55% unchanged), urine 5%; Half-life: 12h

Subclass: Hormonal Oncologics, Antiandrogens ; PARP Inhibitors

Mechanism of Action
for niraparib: inhibits poly (ADP-ribose) polymerase (PARP) enzymes and increases PARP-DNA complex formation, resulting in DNA damage and cell death; for abiraterone acetate: prodrug converted to abiraterone, which inhibits 17 alpha-hydroxylase/C17,20-lyase (CYP17) to block androgen biosynthesis, leading to decr. androgen-sensitive tumor growth (androgen biosynthesis inhibitor)

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Janssen Biotech, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@2af4620b

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information